Global trends and predictions in hepatocellular carcinoma mortality

HBV suppresses ZHX2 expression to promote proliferation of HCC through miR‐155 activation

“…1 While numerous factors contribute to the onset and progression of HCC, chronic infection including hepatitis B virus (HBV) and hepatitis C virus (HCV) are the major risk factors and result in 80% of HCC cases. 1 While numerous factors contribute to the onset and progression of HCC, chronic infection including hepatitis B virus (HBV) and hepatitis C virus (HCV) are the major risk factors and result in 80% of HCC cases.…”

Recent advances in the management of hepatocellular carcinoma: First, cut … is the deepest or is it “no‐touch” and exercise?

“…The literature is populated by studies in afflicted patients who are fortunate enough to access tertiary‐level, city‐based health services that can offer such sophisticated and financially costly interventions . However, a relative paucity of data remains in the reporting of the inequity of access to HCC treatment opportunities and its impact on patient outcomes.…”

“…While the findings of these three studies are enlightening and collectively, hold promise in the care of patients with HCC, in 2019, we should still hold strong to the principle that prevention is better than cure . Capturing cirrhotics in non‐invasive screening programs, improved risk factor management (e.g.…”

Clinical Implications of Augmenter of Liver Regeneration in Cancer: A Systematic Review

“…Background Hepatocellular carcinoma (HCC) is a common oncologic condition with a poor prognosis that poses as a global burden on medical care (1). Between 2002 and 2012 the mortality rate of HCC rose by 34.8% in the United States and liver cancer, with HCC estimated as 70 to 90% of cases, was considered to be the second leading cause of cancer-related deaths among males on a global scale in 2012 (2,3). Considering the metabolic aspect of several known risk factors for HCC, such as obesity, diabetes, and non-alcoholic fatty liver disease, a common underlying feature of mitochondrial dysfunction is of growing interest in molecular oncology.…”